

Haematologica
HAEMATOL/2018/212332
Version 4

Impact of treatment with iron chelation therapy in patients with
lower-risk myelodysplastic syndromes participating in the European
MDS registry

Marlijn Hoeks, Ge Yu, Saskia Langemeijer, Simon Crouch, Louise de Swart, Pierre Fenaux, Argiris Symeonidis, Jaroslav ermák, Eva Hellström-Lindberg, Guillermo Sanz, Reinhard Stauder, Mette Skov Holm, Moshe Mittelman, Krzysztof Mdry, Luca Malcovati, Aurelia Tatic, Antonio Medina Almeida, Ulrich Germing, Aleksandar Savic, Njetoka Gredelj imec, Dominic Culligan, Raphael Itzykson, Agnes Guerci-Bresler, Borhane Slama, Arjan van de Loosdrecht, Corine van Marrewijk, Jackie Droste, Nicole Blijlevens, Marian van Kraaij, David Bowen, Theo de Witte, and Alex Smith
(Collaborative Groups: EUMDS Registry Participants)

Disclosures: PF: Research funding and honoraria of Celgene, Janssen, Novartis, Roche, Amgen, and Astex; ASY: honoraria and consultancy for Amgen, Celgene/GenesisPharma, Janssen-Cilag, Gilead, Pfizer, MSD, Novartis, and Genzyme/Sanofi; EHL: research funding Celgene; GS: honoraria and research funding from Celgene, Novartis, Amgen, advisory committee for Amgen, Boehringer-Ingelheim, Celgene, MSD, and Novartis; MSH: research funding Celgene; AMA: consultancy for Novartis, Celgene, and Servier, honoraria from Bristol Meyer Squibb and Alexion; UG: research funding and honorarium from Novartis; RI: research funding from Oncoethix (now Merck MSD), honoraria from Celgene, Sanofi, Novartis, Amgen, and BMS; CvM: funded by the EUMDS project budget; NB: research funding from Novartis, Bristol Meyer Squibb, Pfizer, Ariad, MSD, Astellas, Xenikos, and Celgene, educational grant from Novartis, Celgene, and Janssen Cilag; TdW: honorarium Novartis as project coordinator EUMDS. The remaining authors (MH, GY, SL, SC, LdS, JC, RS, MM, KM, LM, AT, ASA, NGS, DC, AGB, BS, AvdL, JD, MvK, DB, and AS) declare no competing financial interests.

Contributions: Design: MH, GY, SL, SC, DB, TDW, and AS; provision of patients, assembly of data: GY, SL, LdS, PF, ASY, JC, EHL, GS, RS, MSH, MM, KM, LM, AT, AMA, UG, ASA, NGS, DC, RI, AGB, BS, AvdL, CvM, JD, DB, TdW, and AS; statistical analysis: MH, GY, SL, SC, TDW and AS; manuscript writing: all authors; nal approval: all authors.